Suppr超能文献

相似文献

1
Personalized medicine and the clinical laboratory.
Einstein (Sao Paulo). 2014 Sep;12(3):366-73. doi: 10.1590/s1679-45082014rw2859.
2
Pharmacogenomic biomarkers for personalized cancer treatment.
J Intern Med. 2015 Feb;277(2):201-217. doi: 10.1111/joim.12321.
3
Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17.
4
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
Oncotarget. 2016 Aug 9;7(32):52493-52516. doi: 10.18632/oncotarget.9370.
5
[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1.
6
Future of personalized medicine in oncology: a systems biology approach.
J Clin Oncol. 2010 Jun 1;28(16):2777-83. doi: 10.1200/JCO.2009.27.0777. Epub 2010 Apr 20.
7
Precision Medicine in Pediatric Oncology.
Surg Oncol Clin N Am. 2020 Jan;29(1):63-72. doi: 10.1016/j.soc.2019.08.005. Epub 2019 Oct 29.
8
New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12.
9
Personalized medicine: hope or hype?
Eur Heart J. 2012 Jul;33(13):1564-70. doi: 10.1093/eurheartj/ehs112. Epub 2012 Jun 1.
10
The Personalization of Therapy: Molecular Profiling Technologies and Their Application.
Semin Oncol. 2015 Dec;42(6):775-87. doi: 10.1053/j.seminoncol.2015.09.026. Epub 2015 Sep 30.

引用本文的文献

1
Precision Medicine.
Einstein (Sao Paulo). 2017 Jan-Mar;15(1):VII-X. doi: 10.1590/S1679-45082017ED4016.

本文引用的文献

2
Utility of BCL2, PD1, and CD25 immunohistochemical expression in the diagnosis of T-cell lymphomas.
Appl Immunohistochem Mol Morphol. 2014;22(2):99-104. doi: 10.1097/PAI.0b013e31828ef1f7.
4
Crizotinib for the treatment of non-small-cell lung cancer.
Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261.
5
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.
Int J Clin Oncol. 2014 Apr;19(2):391-6. doi: 10.1007/s10147-013-0562-5. Epub 2013 Apr 23.
6
Diagnostic cancer genome sequencing and the contribution of germline variants.
Science. 2013 Mar 29;339(6127):1559-62. doi: 10.1126/science.1233899.
7
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Pharmacogenomics J. 2014 Apr;14(2):120-9. doi: 10.1038/tpj.2013.10. Epub 2013 Mar 26.
8
Gene expression profiling in breast cancer: a clinical perspective.
Breast. 2013 Apr;22(2):109-120. doi: 10.1016/j.breast.2013.01.016. Epub 2013 Feb 23.
9
Which drug, and when, for patients with BRAF-mutant melanoma?
Lancet Oncol. 2013 Feb;14(2):e60-9. doi: 10.1016/S1470-2045(12)70539-9.
10
Host genetic variants in the pathogenesis of hepatitis C.
Viruses. 2012 Dec;4(12):3281-302. doi: 10.3390/v4123281.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验